Direct in vitro and in vivo comparison of 161Tb and 177Lu using a tumour-targeting folate conjugate

A Unique Matched Quadruplet of Terbium Radioisotopes for PET and SPECT and for  - and  --Radionuclide Therapy: An In Vivo Proof-of-Concept Study with a New Receptor-Targeted Folate Derivative

(2012) C. Muller et al.   JOURNAL OF NUCLEAR MEDICINE

DOTA Conjugate with an Albumin-Binding Entity Enables the First Folic Acid-Targeted 177Lu-Radionuclide Tumor Therapy in Mice

(2012) C. Muller et al.   JOURNAL OF NUCLEAR MEDICINE

Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours

(2011) Jaap J M Teunissen et al.   ENDOCRINE-RELATED CANCER

The low-energy β− and electron emitter 161Tb as an alternative to 177Lu for targeted radionuclide therapy

(2011) Silvia Lehenberger et al.   NUCLEAR MEDICINE AND BIOLOGY

Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues

(2009) Edgar J. Rolleman et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Target burn-up corrected specific activity of 177Lu produced via 176Lu(n, γ) 177Lu nuclear reactions

(2008) K.P. Zhernosekov et al.   APPLIED RADIATION AND ISOTOPES

Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival

(2008) Dik J. Kwekkeboom et al.   JOURNAL OF CLINICAL ONCOLOGY